We are live on ! Find out more
AST.WS

Asterias Biotherapeutics Warrants

Delisted

AST.WS was delisted on the 26th of September, 2017.

33 hedge funds and large institutions have $449K invested in Asterias Biotherapeutics Warrants in 2017 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 6 increasing their positions, 4 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

15,081% more capital inflows, than outflows

Capital inflows: $21.3K | Capital outflows: $140

50% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 4

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

6% less funds holding

Funds holding: 35 → 33 (-2)

50% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 2

Holders
33
Holders Change
-2
Holders Change %
-5.71%
% of All Funds
0.82%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
1
Increased
6
Reduced
4
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

AST.WS Hedge Fund Activity: Q2 2017 in Review

33 of the 4,024 institutional investors tracked by Wall St. Rank reported a position in Asterias Biotherapeutics Warrants (AST.WS) for Q2 2017, worth a combined $449K — up 24% from $362K a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of AST.WS and 1 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 6 added.

The largest buyer was Virtu KCG Holdings, opening a new position worth an estimated $10.4K. The largest seller was Morgan Stanley, cutting an estimated $138.

  • 33 institutional investors held Asterias Biotherapeutics Warrants (AST.WS) as of Q2 2017, down from 35 in Q1 2017.
  • Funds reported $449K of Asterias Biotherapeutics Warrants stock for Q2 2017, up 24% quarter-over-quarter.
  • 1 fund opened new Asterias Biotherapeutics Warrants positions in Q2 2017 and 2 closed out, a net change of -1 holder.
  • The largest Asterias Biotherapeutics Warrants buyer in Q2 2017 was Virtu KCG Holdings, an estimated $10.4K added.
  • The largest Asterias Biotherapeutics Warrants seller in Q2 2017 was Morgan Stanley, an estimated $138 sold.

Based on aggregated 13F filings for Q2 2017.